Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 411

1.

Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.

MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk.

Breast Cancer Res Treat. 2010 Jan;119(2):463-74. doi: 10.1007/s10549-009-0407-0. Epub 2009 May 8. Erratum in: Breast Cancer Res Treat. 2010 Jan;119(2):475.

PMID:
19424794
2.

Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.

MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk.

Breast Cancer Res Treat. 2010 Apr;120(3):727-36. doi: 10.1007/s10549-009-0489-8. Epub 2009 Aug 12.

PMID:
19672706
3.

Modification of menopausal hormone therapy-associated colorectal cancer risk by polymorphisms in sex steroid signaling, metabolism and transport related genes.

Rudolph A, Sainz J, Hein R, Hoffmeister M, Frank B, Försti A, Brenner H, Hemminki K, Chang-Claude J.

Endocr Relat Cancer. 2011 Jun 8;18(3):371-84. doi: 10.1530/ERC-11-0057. Print 2011 Jun.

PMID:
21490239
4.

Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.

Rebbeck TR, Troxel AB, Norman S, Bunin G, DeMichele A, Schinnar R, Berlin JA, Strom BL.

Am J Epidemiol. 2007 Dec 15;166(12):1392-9. Epub 2007 Sep 7. Erratum in: Am J Epidemiol. 2008 Apr 1;167(7):888.

PMID:
17827444
5.

Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: results from the Shanghai Breast Cancer Study and meta-analysis.

Egan KM, Cai Q, Shu XO, Jin F, Zhu TL, Dai Q, Gao YT, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):197-204.

6.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE.

N Engl J Med. 1995 Jun 15;332(24):1589-93.

7.

Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk.

Quick SK, Shields PG, Nie J, Platek ME, McCann SE, Hutson AD, Trevisan M, Vito D, Modali R, Lehman TA, Seddon M, Edge SB, Marian C, Muti P, Freudenheim JL.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1082-7. doi: 10.1158/1055-9965.EPI-07-2755.

8.

Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.

Hein R, Abbas S, Seibold P, Salazar R, Flesch-Janys D, Chang-Claude J.

Breast Cancer Res Treat. 2012 Jan;131(2):653-61. doi: 10.1007/s10549-011-1772-z. Epub 2011 Sep 23.

PMID:
21947678
9.

Postmenopausal estrogen and progestin use in relation to breast cancer risk.

Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600.

10.
11.

A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.

Singh V, Rastogi N, Sinha A, Kumar A, Mathur N, Singh MP.

Breast Cancer Res Treat. 2007 Jan;101(1):73-81. Epub 2006 Jun 29. Erratum in: Breast Cancer Res Treat. 2007 Apr;102(2):249.

PMID:
16807674
12.

Breast cancer risk with postmenopausal hormonal treatment.

Collins JA, Blake JM, Crosignani PG.

Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. Epub 2005 Sep 8. Review. Erratum in: Hum Reprod Update. 2006 May-Jun;12(3):331.

PMID:
16150813
13.
14.

Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians.

Shimada N, Iwasaki M, Kasuga Y, Yokoyama S, Onuma H, Nishimura H, Kusama R, Hamada GS, Nishimoto IN, Iyeyasu H, Motola J Jr, Laginha FM, Kurahashi N, Tsugane S.

J Hum Genet. 2009 Apr;54(4):209-15. doi: 10.1038/jhg.2009.13. Epub 2009 Feb 20.

PMID:
19229255
15.

A systematic approach to analysing gene-gene interactions: polymorphisms at the microsomal epoxide hydrolase EPHX and glutathione S-transferase GSTM1, GSTT1, and GSTP1 loci and breast cancer risk.

Spurdle AB, Chang JH, Byrnes GB, Chen X, Dite GS, McCredie MR, Giles GG, Southey MC, Chenevix-Trench G, Hopper JL.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):769-74.

16.

GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking.

Schneider J, Bernges U, Philipp M, Woitowitz HJ.

Cancer Lett. 2004 May 10;208(1):65-74.

PMID:
15105047
17.

HSD17B1 gene polymorphisms and risk of endometrial and breast cancer.

Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I.

Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):213-9.

18.

Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk.

Park SK, Yim DS, Yoon KS, Choi IM, Choi JY, Yoo KY, Noh DY, Choe KJ, Ahn SH, Hirvonen A, Kang D.

Breast Cancer Res Treat. 2004 Nov;88(1):55-62.

PMID:
15538046
19.

Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk.

Mitrunen K, Kataja V, Eskelinen M, Kosma VM, Kang D, Benhamou S, Vainio H, Uusitupa M, Hirvonen A.

Pharmacogenetics. 2002 Jan;12(1):67-72.

PMID:
11773866
20.

Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology.

Rebbeck TR, Troxel AB, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Norman S, Bunin G, DeMichele A, Berlin M, Schinnar R, Berlin JA, Strom BL.

Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):444-50.

Supplemental Content

Support Center